Bristol-myers Squibb Compnay

Viiv Healthcare UK (no.5) Limited

Viiv Healthcare UK Limited

Brett R Beno

John A Bender

John F Kadow

Kap-Sun Yeung

Piyasena Hewawasam

Kyle E Parcella

Katharine A Grant-Young

Ying Han

Andrew Nickel

Nicholas A Meanwell

Makonen Belema

Annapurna Pendri

Robert G Gentles

Louis Stanley Chupak

Zhong Yang

Richard Pracitto

Alicia Regueiro-Ren

Jacob Swidorski

Alan Xiangdong Wang

Manoranjan Panda

Guo Li

Robert A Fridell

Guanglin Luo

Prasad V Chaturvedula

Gan Wang

Van N Nguyen

Ramakanth Sarabu

Satheesh Kesavan Nair

Graham S Poindexter

Prasada Rao Jalagam

Srinivasan Thangathirupathy

Shirong Zhu

Rajesh Onkardas Bora

David S Yoon

Selvakumar Kumaravel

Shikha Vig

Mallikarjuna Rao Mettu

Shilpa Maheshwarappa Holehatti

The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

Small molecule inhibitors of galectin-3

The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. 

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: 

Inhibitors of human immunodeficiency virus replication

Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth: 

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

Compounds for the treatment of hepatitis C

The disclosure provides compounds of formula I, II, III, IV, and V, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Novel azetidinyl and pyrrolidinyl compounds are ligands of melanocortin-4 receptors and are useful for treating conditions responsive to the modulation of melanocortin-4 receptors such as obesity, diabetes, and sexual dysfunction. 

Amidoheterocycles as modulators of the melanocortin-4 receptor

Growing community of inventors

Cromwell, CT, United States of America

Brett R Beno